Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes
- 1 June 2005
- journal article
- review article
- Published by Elsevier BV in Diabetes & Metabolism
- Vol. 31 (3), 233-242
- https://doi.org/10.1016/s1262-3636(07)70190-8
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 DiabetesDiabetes Care, 2004
- GLP‐1 receptor agonists are growth and differentiation factors for pancreatic islet beta cellsDiabetes/Metabolism Research and Reviews, 2003
- GIF biology and fat metabolismLife Sciences, 1999
- Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.International Journal of Obesity, 1999
- Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.JCI Insight, 1998
- Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.JCI Insight, 1993
- Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic SubjectsDiabetes Care, 1992
- GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MANThe Lancet, 1987
- Oral Glucose Augmentation of Insulin SecretionJCI Insight, 1978
- Entero-insular axisArchives of Internal Medicine, 1969